The Use of Cabazitaxel in Men with Castrate Resistant Metastatic Prostate Cancer Previously Treated with Docetaxel

This special advice report reviews the use of cabazitaxel, either alone or in combination, as a treatment for adult patients with castrate resistant metastatic prostate cancer who have been previously treated with a docetaxel-containing regimen. Outcomes of interest include treatment efficacy and adverse events.